Summary of Key Information:
Reporting Period: Quarter and Financial Year ended March 31, 2026
Nature of Filing / Announcement: Audited Financial Results (Standalone and Consolidated)
Audit Opinion:
Unmodified Opinion by Statutory Auditors (Mittal Agarwal & Company, FRN: 131025W)
Key Financial Highlights [Rs. in Lakhs]:
Standalone Results:
Revenue from Operations:
- Q4 FY26: ₹25,205.23 (vs ₹20,502.01 in Q4 FY25, +22.9% YoY)
- FY26: ₹94,047.54 (vs ₹81,980.59 in FY25, +14.7% YoY)
Total Income:
- Q4 FY26: ₹25,085.65
- FY26: ₹94,305.75
Net Profit:
- Q4 FY26: ₹2,057.44 (vs ₹797.41 in Q4 FY25, +158.1% YoY)
- FY26: ₹6,314.87 (vs ₹6,993.28 in FY25, -9.7% YoY)
EPS:
- Basic & Diluted: Q4 FY26: ₹2.05; FY26: ₹6.30
Other Equity Reserves:
- FY26: ₹65,415.42 (vs ₹59,133.51 in FY25)
Consolidated Results:
Revenue from Operations:
- Q4 FY26: ₹25,181.97 (vs ₹20,502.01 in Q4 FY25, +22.8% YoY)
- FY26: ₹94,400.66 (vs ₹81,980.59 in FY25, +15.2% YoY)
Total Income:
- Q4 FY26: ₹25,064.59
- FY26: ₹94,666.40
Net Profit:
- Q4 FY26: ₹2,189.61 (vs ₹771.95 in Q4 FY25, +183.7% YoY)
- FY26: ₹6,421.47 (vs ₹6,964.95 in FY25, -7.8% YoY)
EPS:
- Basic & Diluted: Q4 FY26: ₹2.18; FY26: ₹6.40
Other Equity Reserves:
- FY26: ₹65,492.03 (vs ₹59,104.90 in FY25)
Segment-wise Performance:
The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
Corporate Actions:
Dividend: The Board recommended a final dividend of Re. 0.10 per equity share (10% on face value of Re. 1 each) for financial year 2025-26, subject to approval of shareholders at the ensuing Annual General Meeting.
Cash Flow Information [Rs. in Lakhs]:
Standalone:
- Net cash from operating activities: ₹4,401.97 (FY26) vs ₹12,277.77 (FY25)
- Net cash used in investing activities: ₹(3,096.42) (FY26) vs ₹(7,179.12) (FY25)
- Net cash from financing activities: ₹3,236.06 (FY26) vs ₹(3,720.41) (FY25)
- Cash and cash equivalents at end: ₹6,032.49 (FY26) vs ₹1,490.88 (FY25)
Consolidated:
- Net cash from operating activities: ₹4,496.78 (FY26) vs ₹12,256.80 (FY25)
- Net cash used in investing activities: ₹(3,096.42) (FY26) vs ₹(7,077.73) (FY25)
- Net cash from financing activities: ₹3,246.08 (FY26) vs ₹(3,720.41) (FY25)
- Cash and cash equivalents at end: ₹6,218.59 (FY26) vs ₹1,572.33 (FY25)
Entities Included in Consolidation:
1. Gufic Prime Private Limited (Subsidiary)
2. Gufic UK Limited (Wholly Owned Foreign Subsidiary)
3. Veira Life FZE (Wholly Owned Foreign Subsidiary)
4. Gufic Ireland Limited (Wholly Owned Foreign Subsidiary)
Other Significant Information:
The financial results include balancing figures for the quarter ended March 31, 2026 between audited full year figures and published unaudited figures for nine months ended December 31, 2025.
Previous year/quarter figures have been regrouped/reclassified where necessary.